Parkwood LLC’s Seres Therapeutics MCRB Stock Holding History

Parkwood LLC’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-703	Closed	-$345K	–	124
2020 Q4	$345K	Buy	+703	New	+$412K	0.04%	107

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkwood LLC's MCRB Position: Q1 2021 in Review

Parkwood LLC sold out of Seres Therapeutics (MCRB) in Q1 2021, closing a stake of 703 shares — an estimated $345K sold.

Parkwood LLC first reported a position in MCRB in Q4 2020 and held it in 1 quarter. The position peaked at $345K in Q4 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q1 2021.

Parkwood LLC reported no remaining Seres Therapeutics position as of Q1 2021 after selling out during the quarter.
Parkwood LLC sold 703 Seres Therapeutics shares in Q1 2021, an estimated $345K.
Parkwood LLC first reported a position in Seres Therapeutics in Q4 2020 and held it in 1 quarter.
Parkwood LLC's Seres Therapeutics position peaked at $345K in Q4 2020.
152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2021.

Based on Parkwood LLC's 13F filing for Q1 2021, filed 14 May 2021.